Interim Report January – March 2022
Aktiedagen Stockholm – May 2, 2022
Sedermeradagen – April 25, 2022
AP1189
A Novel and First-in-Class Agent to Target the Melanocortin System
Our lead drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors – a distinct mode of action compared to approved anti-inflammatory drugs which can be immunosuppressive. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by COVID-19 infection.
-
June 28, 2022 RegulatorySynAct Pharma AB has been approved for listing on Nasdaq Stockholm
-
June 21, 2022 Non RegulatorySynAct Pharma submits CTA for Clinical Phase 2b Study in RA
-
May 30, 2022 RegulatorySynAct Pharma publishes Q1 2022 interim report
-
April 29, 2022 RegulatorySynAct Pharma AB publishes Annual Report 2021
